Keywords: Eisai, Halaven, Breast cancer, Switzerland, Approval

Eisai gets Swiss approval for Halaven

Article | 19 May 2011

Print This

Japanese drug major Eisai (TYO: 4532), says that its Halaven(eribulin) has been approved for use in Switzerland by Swissmedic, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in